%0 Journal Article %A Nai-Xin Liang %A Tao Wang %A Cong Zhang %A Zichen Jiao %A Tianqiang Song %A Hongwei Liang %A Qihan Chen %T New Role of Red Blood Cells in Absorption of DNA Bearing Tumorigenic Mutations from Lung Cancer Tissue %D 2021 %R 10.1101/2021.01.15.21249747 %J medRxiv %P 2021.01.15.21249747 %X Red blood cells (RBC) are commonly assumed to be vehicles for oxygen, carbon dioxide, and cells’ metabolic byproducts. In this study, we investigated whether RBC may contain cancer-cell derived DNA and whether such cargo may be used as a biomarker for detecting cancer. Using an in vitro co-culture system, we showed that RBC could absorb DNA bearing tumorigenic mutations from cancer cell lines. Next, we demonstrated that we could detect common genetic mutations, including EGFR 19 deletion, L858R, and KRAS G12 in RBC collected from early-stage non-small cell lung cancer patients. We were able to repeat our finding using both next-generation sequencing and droplet digital PCR. Our study highlights a new biological phenomenon involving RBC and their translational potential as a novel liquid biopsy technology platform that can be used for early cancer screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo Applicable FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Both ethics committees of Nanjing Drum Tower Hospital and Beijing Union Medical College Hospital approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall relevant data is shown in the tables provided. %U https://www.medrxiv.org/content/medrxiv/early/2021/01/24/2021.01.15.21249747.full.pdf